| Filed On | Filing |
|---|---|
| 20 Oct 2026 | REGISTRATION STATEMENT |
| 01 Oct 2026 |
8-K: Regulation FD Disclosure
Forward-Looking Statements 2 Safe Harbor Statement This presentation and any accompanying oral discussion contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not ... |
| 28 Sep 2026 | SCHEDULE 13G/A |
| 25 Sep 2026 |
Form 4: Whitfield Roy A, Director
Received 2,000 shares as a grant or award · Granted 4,000 Stock Option |
| 25 Sep 2026 |
Form 4: Greer R Scott, Director
Received 2,000 shares as a grant or award · Granted 4,000 Stock Option |
| 25 Sep 2026 |
Form 4: Chess Robert, Director
Received 2,000 shares as a grant or award · Granted 4,000 Stock Option |
| 25 Sep 2026 |
Form 4: Brainard Diana, Director
Received 2,000 shares as a grant or award · Granted 4,000 Stock Option |
| 25 Sep 2026 |
Form 4: Ajer Jeffrey Robert, Director
Received 2,000 shares as a grant or award · Granted 4,000 Stock Option |
| 25 Sep 2026 |
8-K: Other Events
In August 2023, Nektar Therapeutics (the “Company”) filed a complaint in the U.S. District Court for the Northern District of California (the “District Court”) against Eli Lilly and Company (“Lilly”) alleging, among other claims, breach ... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Nektar Therapeutics (the “Company”) is entering a quiet period beginning September 8, 2026 and continuing until the public announcement of data from the 24-week off treatment follow-up period of its Phase 2b REZOLVE-AA study of rezpegald... |
| 20 Aug 2026 |
Form 4: Zalevsky Jonathan, Chief R&D Officer
Sold 186 shares ($13.4K) |
| 20 Aug 2026 |
Form 4: Robin Howard W, Director
Sold 418 shares ($30.1K) |
| 18 Aug 2026 | 144 |
| 18 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | REGISTRATION STATEMENT |
| 14 Aug 2026 | 10-Q |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 31 Jul 2026 | SCHEDULE 13G |
Loading...
